2-(3-oxo-2,4-dihydroquinoxalin-1-yl)-2-phenyl-N-(4-propan-2-ylphenyl)acetamide is a complex organic molecule with a rather lengthy chemical name. It's important to understand what this name tells us about the molecule's structure before discussing its potential research significance.
**Breaking Down the Name**
* **2-(3-oxo-2,4-dihydroquinoxalin-1-yl):** This part describes a substituted quinoxaline ring system.
* **Quinoxaline:** A heterocyclic ring system composed of two fused benzene rings with a nitrogen atom at each junction.
* **3-oxo:** This indicates a carbonyl (C=O) group is attached to the third carbon atom of the quinoxaline ring.
* **2,4-dihydro:** This signifies that the second and fourth positions on the quinoxaline ring are saturated (have two hydrogen atoms attached).
* **1-yl:** This indicates that the quinoxaline ring is attached to the rest of the molecule at the first position.
* **2-phenyl:** This describes a phenyl group (a benzene ring) attached to the second position of the molecule.
* **N-(4-propan-2-ylphenyl):** This refers to an amide group (containing a nitrogen atom) connected to a phenyl group.
* **N-:** This indicates that the amide group is directly attached to the nitrogen atom.
* **4-propan-2-yl:** This indicates an isopropyl group (CH(CH3)2) is attached to the fourth position of the phenyl ring.
**Overall, the molecule can be visualized as:**
* A quinoxaline ring system with a carbonyl group at position 3 and attached to a phenyl group and an amide group.
* The amide group is connected to a phenyl ring that also has an isopropyl group.
**Potential Research Importance**
Due to the complex structure and functional groups present, this molecule could be interesting for research in several areas:
* **Pharmacology:** The presence of the quinoxaline ring and amide group suggests potential for biological activity. Many quinoxaline derivatives have been found to possess antibacterial, antifungal, anti-inflammatory, and anticancer activities. This molecule could be investigated for its potential pharmacological properties.
* **Materials Science:** The presence of both aromatic rings (quinoxaline and phenyl) and a carbonyl group indicates the molecule could exhibit interesting optical or electronic properties. It could be investigated for use in organic electronics, sensors, or other advanced materials.
* **Organic Synthesis:** The complexity of the molecule makes it a potential target for organic synthesis research. Synthesizing this molecule could involve challenging reaction steps and might lead to the development of new synthetic methodologies.
**It's important to note that without specific research context, it's difficult to definitively say why this molecule is important for research. The molecule's actual significance will depend on the specific research questions being investigated.**
ID Source | ID |
---|---|
PubMed CID | 4384031 |
CHEMBL ID | 1527084 |
CHEBI ID | 114555 |
Synonym |
---|
CHEMDIV3_007555 , |
IDI1_025465 |
MLS000586757 |
smr000208687 |
n-(4-isopropylphenyl)-2-(3-oxo-3,4-dihydroquinoxalin-1(2h)-yl)-2-phenylacetamide |
EU-0054660 |
CHEBI:114555 |
HMS1494H09 |
2-(3-oxo-2,4-dihydroquinoxalin-1-yl)-2-phenyl-n-(4-propan-2-ylphenyl)acetamide |
n-(4-isopropylphenyl)-2-[3-oxo-3,4-dihydro-1(2h)-quinoxalinyl]-2-phenylacetamide |
AKOS001776550 |
AKOS022028135 |
CHEMBL1527084 |
Q27195958 |
sr-01000548827 |
SR-01000548827-1 |
Class | Description |
---|---|
amino acid amide | An amide of an amino acid formed formally by conversion of the carboxy group to a carboxamido group. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASE | Homo sapiens (human) | Potency | 0.2239 | 0.0032 | 45.4673 | 12,589.2998 | AID2517 |
Luciferase | Photinus pyralis (common eastern firefly) | Potency | 15.1014 | 0.0072 | 15.7588 | 89.3584 | AID588342 |
glp-1 receptor, partial | Homo sapiens (human) | Potency | 1.0000 | 0.0184 | 6.8060 | 14.1254 | AID624417 |
chaperonin-containing TCP-1 beta subunit homolog | Homo sapiens (human) | Potency | 11.2202 | 3.9811 | 27.7649 | 39.8107 | AID504842 |
ATAD5 protein, partial | Homo sapiens (human) | Potency | 14.5810 | 0.0041 | 10.8903 | 31.5287 | AID504467 |
USP1 protein, partial | Homo sapiens (human) | Potency | 1.2589 | 0.0316 | 37.5844 | 354.8130 | AID743255 |
Smad3 | Homo sapiens (human) | Potency | 10.0000 | 0.0052 | 7.8098 | 29.0929 | AID588855 |
aldehyde dehydrogenase 1 family, member A1 | Homo sapiens (human) | Potency | 31.6228 | 0.0112 | 12.4002 | 100.0000 | AID1030 |
isocitrate dehydrogenase 1, partial | Homo sapiens (human) | Potency | 32.4648 | 6.3096 | 27.0990 | 79.4328 | AID602179; AID624002 |
serine-protein kinase ATM isoform a | Homo sapiens (human) | Potency | 35.4813 | 0.7079 | 25.1119 | 41.2351 | AID485349 |
chromobox protein homolog 1 | Homo sapiens (human) | Potency | 89.1251 | 0.0060 | 26.1688 | 89.1251 | AID540317 |
mitogen-activated protein kinase 1 | Homo sapiens (human) | Potency | 10.0000 | 0.0398 | 16.7842 | 39.8107 | AID1454 |
nuclear receptor ROR-gamma isoform 1 | Mus musculus (house mouse) | Potency | 22.3872 | 0.0079 | 8.2332 | 1,122.0200 | AID2551 |
geminin | Homo sapiens (human) | Potency | 29.0929 | 0.0046 | 11.3741 | 33.4983 | AID624296 |
DNA dC->dU-editing enzyme APOBEC-3F isoform a | Homo sapiens (human) | Potency | 17.7828 | 0.0259 | 11.2398 | 31.6228 | AID602313 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (20.00) | 29.6817 |
2010's | 3 (60.00) | 24.3611 |
2020's | 1 (20.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.56) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 5 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |